Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656556 | 0.93 | GRM4 (0.55) | BACE1CNR1GRM4GAAKDM4E | |
| SCHEMBL14012061 | 0.84 | BACE1 (0.56) | BACE1GRM4GAAKDM4EMEN1 | |
| SCHEMBL4606123 | 0.81 | BACE1 (0.53) | BACE1GRM4GAAKDM4EMEN1 | |
| SCHEMBL4452291 | 0.81 | BACE1 (0.62) | BACE1GRM4GAAKDM4EMEN1 | |
| SCHEMBL13962883 | 0.81 | BACE1 (0.62) | BACE1GRM4GAAMEN1KMT2A | |
| SCHEMBL13962869 | 0.80 | BACE1 (0.60) | BACE1GRM4GAAKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL4603331 | 0.80 | BACE1 (0.60) | BACE1GRM4GAAKDM4EMEN1 | |
| SCHEMBL4558113 | 0.80 | BACE1 (0.64) | BACE1GRM4GAAKDM4EMEN1 | |
| SCHEMBL9469239 | 0.80 | NPC1 (0.52) | GRM4KDM4EMEN1KMT2AKDR | |
| SCHEMBL14284354 | 0.73 | TLR7 (0.67) | GRM4KDM4EKDRNPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005567-A1 | PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | ZACH SYSTEM S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| US-20090005567-A1 | PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | ZACH SYSTEM S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| US-7449583-B2 | Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) | ZACH SYSTEM S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-7449583-B2 | Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine) | ZACH SYSTEM S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| CN-1257166-C | Process for preparing tricyclic compound having antihistaminic activity | SCHERING CORP (US) | 2006-05-24 | — | — | CN | disclosed |
| EP-1140899-B1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORP (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6495689-B2 | DEHYDRATING COMPOUND COMPRISING 2-AMIDO ARYL OR HETEROARYL-3-ETHYLPHENYL-PYRIDINE COMPOUND TO FORM IMINE DERIVATIVE; HYDROLYSIS TO FORM (SUBSTITUTED) 5,6-DIHYDRO-11HBENZO(5,6)CYCLOHEPTA(1,2B)PYRID-11-ONE COMPOUND | SCHERING CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020077331-A1 | Synthesis of intermediates useful in preparing tricyclic compounds | MERCK SHARP & DOHME CORP. | 2002-06-20 | — | — | US | disclosed |
| US-6372909-B1 | REACTING 3-PHENYLETHYL-2-PYRIDINECARBOXAMIDE WITH DEHYDRATING AGENT TO CYCLIZE AND FORM TRICYCLIC IMINE, HYDROLYZING TO FORM TRICYCLIC KETONE | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| CN-1334810-A | Process for preparing tricyclic compound having antihistaminic activity | SCHERING CORP (US) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140899-A1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1131296-A2 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6271378-B1 | Process for preparing tricyclic compounds having antihistaminic activity | SCHERING CORPORATION | 2001-08-07 | — | — | US | disclosed |
| WO-2000037457-A1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000030589-A2 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005567-A1 | PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) | HRH4, HRH2, GRIN3A | BACE1 3426/4885CNR1 129/4885GRM4 26/4885 |
| US-20020077331-A1 | Synthesis of intermediates useful in preparing tricyclic compounds | CBR1, CYP2F1, REV1 | BACE1 2672/4885CNR1 140/4885GRM4 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.